Belimumab (BENLYSTA®) Pregnancy Registry
This study is currently recruiting participants.
Verified January 2013 by GlaxoSmithKline
Sponsor:
GlaxoSmithKline
Collaborator:
PPD
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01532310
First received: February 2, 2012
Last updated: January 24, 2013
Last verified: January 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This global Belimumab Pregnancy Registry will collect prospective data on pregnancies and pregnancy outcomes on a voluntary basis in women with systemic lupus erythematosus (SLE) who have received commercially supplied belimumab within the 4 months prior to and/or during pregnancy. The registry will also evaluate outcomes of infants born to mothers who were exposed to belimumab within the 4 months prior to and/or during pregnancy. This registry will add to the current clinical experience with belimumab and will complement reproductive data from animal toxicology studies. It will also assist clinicians in weighing the potential risks against the benefits of treatment for individual patients with SLE. GlaxoSmithKline (GSK) will sponsor the Belimumab Pregnancy Registry in countries where it holds Marketing Authorization.
| Condition | Intervention |
|---|---|
|
Birth Defects Infant Outcomes Systemic Lupus Erythematosus Adverse Pregnancy Outcomes Pregnancy |
Drug: belimumab |
| Study Type: | Observational [Patient Registry] |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Target Follow-Up Duration: | 7 Years |
| Official Title: | Belimumab (BENLYSTA®) Pregnancy Registry (BPR) - Prospective Cohort Study of Pregnancy Outcomes Following Benlysta Exposure Within 4 Months Prior to and/or During Pregnancy |
Resource links provided by NLM:
Further study details as provided by GlaxoSmithKline:
Primary Outcome Measures:
- Birth defects [ Time Frame: Up to one year after birth ] [ Designated as safety issue: Yes ]The registry will define and code birth defects with criteria specified by Centers for Disease Control and Prevention (CDC)'s Metropolitan Atlanta Congenital Defects Program (MACDP)
Secondary Outcome Measures:
- Other pregnancy outcomes [ Time Frame: At birth ] [ Designated as safety issue: Yes ]Other pregnancy outcomes including spontaneous miscarriage, live birth (including pre-term birth and small for gestational age), stillbirth, and elective termination
- Infant outcomes [ Time Frame: Up to 1 year after birth ] [ Designated as safety issue: Yes ]Serious and/or clinically significant infections
| Estimated Enrollment: | 500 |
| Study Start Date: | July 2012 |
| Estimated Study Completion Date: | May 2019 |
| Estimated Primary Completion Date: | May 2019 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
Pregnant women taking belimumab
Any women with belimumab exposure within the 4 months prior to and/or during pregnancy
|
Drug: belimumab
Belimumab is a recombinant, human, IgG1λ monoclonal antibody for the treatment of systemic lupus erythematosus
|
|
Infants
Infants through the first year of life whose mothers were exposed to belimumab during pregnancy
|
Drug: belimumab
Belimumab is a recombinant, human, IgG1λ monoclonal antibody for the treatment of systemic lupus erythematosus
|
Eligibility| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Women with SLE who have been exposed to commercially supplied belimumab within the 4 months prior to and/or during pregnancy will be eligible to participate in the registry as well as their infants.
Criteria
Inclusion Criteria:
- Pregnant women containing sufficient evidence to confirm that exposure to commercially supplied belimumab occurred within the 4 months prior to and/or during pregnancy
- Pregnant women with sufficient information to classify the pregnancy as prospective or retrospective (ie,whether the outcome of pregnancy was known at the time of first contact with the registry)
- Pregnant women with full contact information to allow for follow-up (name, address, telephone number/email address) and contact information for applicable HCPs if initial reporter is the pregnant woman
- Consent provided by the pregnant woman for her participation and assent for participation of her infant.
Exclusion Criteria:
- Reported cases that do not meet the minimum inclusion criteria for registry enrollment will be ineligible for inclusion in the registry
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01532310
Contacts
| Contact: US GSK Clinical Trials Call Center | 877-379-3718 | GSKClinicalSupportHD@gsk.com |
Locations
| United States, North Carolina | |
| GSK Investigational Site | Recruiting |
| Wilmington, North Carolina, United States, 28401 | |
| Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com | |
| Contact: EU Clinical Trials Call Center +44 (0) 20 8990 4466 GSKClinicalSupportHD@gsk.com | |
Sponsors and Collaborators
GlaxoSmithKline
PPD
Investigators
| Study Director: | GSK Clinical Trials | GlaxoSmithKline |
More Information
Additional Information:
No publications provided
| Responsible Party: | GlaxoSmithKline |
| ClinicalTrials.gov Identifier: | NCT01532310 History of Changes |
| Other Study ID Numbers: | 114256, WEUKBRE6076 |
| Study First Received: | February 2, 2012 |
| Last Updated: | January 24, 2013 |
| Health Authority: | Europe: No Health Authority United States: No Health Authority Canada: No Health Authority |
Keywords provided by GlaxoSmithKline:
|
systemic lupus erythematosus belimumab pregnancy |
Additional relevant MeSH terms:
|
Congenital Abnormalities Lupus Erythematosus, Systemic Connective Tissue Diseases Autoimmune Diseases Immune System Diseases |
ClinicalTrials.gov processed this record on May 23, 2013